With various product and process patents filed, Glenmark’s Intellectual Property (IP) team is not only an integral part of Glenmark API but also an integral part of the drug development process. 

Furthermore, with over 125 scientists spread across a modern 70,000 sq. ft. Research Center equipped with X-ray Diffractors, in-house particle size capabilities, and HPLCs equipped with a variety of detection systems, Glenmark has established itself among the top Generic R&D Companies in the world. Leveraging this human capital and infrastructure has allowed Glenmark API to develop some truly unique and challenging Active Pharmaceutical Ingredients. 

With three API manufacturing plants located in Ankleshwar, Kurkumbh, and Mohol in India, Glenmark has robust manufacturing capabilities. The Ankleshwar plant has been inspected by the United States Food & Drug Administration as well as Britain's Medicines and Healthcare products Regulatory Agency. Our high standards for manufacturing and processing have enabled us to partner with some leading generics companies to supply various Active Ingredients. 

We operate with various Governments and Regulatory Agencies and have a strong Regulatory Affairs Team in place. Moreover, our logistics team coordinates internally and externally to ensure all products are received on time, every time.